INTRODUCTION

Type 1 diabetes (T1D) are characterized by a targeted autoimmune destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans and the ensuing insufficient insulin production. The different degrees of β-cell dysfunction lead to chronic hyperglycaemia accompanied by an inflammatory reaction and immune responses that affect major organs including eyes, nerves, heart, blood vessels and kidneys. A major feature of diabetic kidney disease is the apoptosis of tubular epithelial cells as a result of increased free radicals production and amplified oxidative stress under the hyperglycaemic condition. Most of the current studies on T1D use animal models that promptly develop severe disease after administration of diabetogenic substances, such as streptozotocin or alloxan. To address the early...

Abstract

Nephropathy is a major chronic complication of diabetes. A crucial role in renal pathophysiology is played by hydrogen sulphide (H₂S) that is produced excessively by the kidney; however, the data regarding H₂S bioavailability are inconsistent. We hypothesize that early type 1 diabetes (T1D) increases H₂S production by a mechanism involving hyperglycaemia-induced alterations in sulphur metabolism. Plasma and kidney tissue collected from T1D double transgenic mice were subjected to mass spectrometry-based proteomic analysis, and the results were validated by immunological and gene expression assays. T1D mice exhibited a high concentration of H₂S in the plasma and kidney tissue and histological, showed signs of subtle kidney fibrosis, characteristic for early renal disease. The shotgun proteomic analyses disclosed that the level of enzymes implicated in sulphate activation modulators, H₂S-oxidation and H₂S-production were significantly affected (ie 6 up-regulated and 4 down-regulated). Gene expression results corroborated well with the proteomic data. Dysregulation of H₂S enzymes underly the changes occurring in H₂S production, which in turn could play a key role in the initiation of renal disease. The new findings lead to a novel target in the therapy of diabetic nephropathy. Mass spectrometry data are available via ProteomeXchange with identifier PXD018053.
changes occurring in diabetic nephropathy, we chose to employ double transgenic diabetic mice (dTg) that, between the 3rd and the 8th week of age, develops gradually T1D with somatic, metabolic and vascular disorders comparable to human diabetes.3–5 These characteristics allow the study of the etiopathogenic mechanisms of early diabetic nephropathy, the understanding of which could open up the possibility of finding new targets for the therapy of this disease.

Hydrogen sulphide (H₂S) is produced redundantly by the kidney and has a crucial role in renal physiology (ie regulation of the excretory function of the kidney, release of renin and oxygen sensor) and pathology (ie renal ischaemia/reperfusion, obstructive or hypertensive nephropathy). H₂S is a colourless, water-soluble and membrane-permeable gas, considered the third gaseous signalling molecule after nitric oxide and carbon monoxide. It is generated through the cysteine metabolism by cystathionine β-synthase (Cbs) and cystathionine γ-lyase (Cth) enzymes or by the concerted action of cysteine aminotransferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst). Recent studies reveal a complex role for H₂S transferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst). Recent studies reveal a complex role for H₂S metabolism by cystathionine β-synthase (Cbs) and cystathionine γ-lyase (Cth) enzymes or by the concerted action of cysteine aminotransferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst). Recent studies reveal a complex role for H₂S transferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst). Recent studies reveal a complex role for H₂S transferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst). Recent studies reveal a complex role for H₂S transferase, D-amino acid oxidase (Dao) and 3-mercaptopyruvate sulphotransferase (Mpst).

In streptozotocin-treated murine animal models, H₂S has been reported as a protective molecule, playing a key role in the reduction of endothelial dysfunction, cardiomyopathy and nephropathy.6 Addressing the role of H₂S in diabetes, Xie et al demonstrated for the first time that H₂S suppresses diabetes-induced accelerated atherosclerosis.12,13 However, there are no consistent data on the H₂S role and its concentration in the plasma and different tissues of the diabetic patients and experimental animal models.14,15 Some studies argue that the plasma H₂S level in streptozotocin-induced diabetic rats is reduced16 while others, on similar animal models report unchanged plasma levels of H₂S, although insulin administration results in increased plasma H₂S concentration.15

Thus, due to its importance, we examined the changes occurring in the plasma and kidney concentration of H₂S level in early T1D and questioned the underlying mechanisms of this alteration. We hypothesize that hyperglycaemia deregulates the enzymes involved in H₂S metabolism, which in turn change the equilibrium of H₂S production that could play an important role in the onset of early kidney dysfunction in diabetes.

To test this hypothesis, we designed experiments using a double transgenic diabetic mouse model and high-performance mass spectrometry-based proteomic analysis. Hereby, we present data showing that in diabetes there’s an increase in circulating H₂S and the diabetic kidney exhibits significantly differentially expressed enzymes implicated in sulphur metabolism. The results provide new markers of kidney dysfunction that could become novel therapeutic targets in T1D complications.

2 MATERIALS AND METHODS

All chemicals used for liquid chromatography (LC) and mass spectrometry (MS) experiments were of LC-MS grade. Trypsin Gold was purchased from Promega. Urea, sodium deoxycholate (DOC), Trizma hydrochloride (Tris), DL-dithiothreitol (DTT), iodoacetamide (IAA), N-acetyl-L-cysteine (NAC), ethylenediaminetetraacetic acid (EDTA), bovine serum albumin (BSA), ammonium bicarbonate and all solvents were provided by Sigma-Aldrich, unless otherwise specified. Complete protease inhibitor cocktail was offered by Roche. C18 solid-phase extraction (SPE) columns were acquired from Waters Corporation. Protein concentration was determined by amido black assay using Amido Black 10B (JT Baker Chemical Co.). Cholesterol, glucose and triglyceride plasma levels were determined using the specific assays from DIALAB GMBH. The concentration of renal plasma and renal tissue H₂S were determined by the H₂S Assay Kit E-BC-K355 (Elabscience) according to the manufacturer’s instructions.

2.1 Experimental animal models

Twenty transgenic mice were from the ‘Cantacuzino’ National Institute of Research and Development for Microbiology and Immunology (Bucharest, Romania) and housed in suitable facility under controlled temperature, humidity and 12 hours light cycle. The Ins-HA+/TCR-HA+/ double transgenic Balb/c mice (dTg) were obtained as previously described.3,4 Briefly, the mice express simultaneously the hemagglutinin (HA) of influenza virus under the rat insulin promoter (Ins-HA) and T cell receptor (TCR) specific for the immunodominant CD4 T cell epitope of HA (HA110-120) in pancreatic β-cells. Since the Ins-HA+/TCR-HA+/ mice were homozygous and the TCR-HA+/Tg mice were heterozygous, the offspring were either Ins-HA+/TCR-HA+/ (dTg) mice (which developed diabetes) or Ins-HA+/TCR-HA−/Tg mice (which did not develop diabetes). As controls, we employed both, the single transgenic, Ins-HA+/ TCR-HA−/Tg and the wild-type Balb/c mice (WT). The animals were divided in three experimental groups, ten animals per group: (a) double transgenic mice (dTg) that developed autoimmune T1D; (b) single transgenic mice (sTg); and (c) BALB/c mice (WT). During the experiments, the animals had free access to standard diet and freshwater. After 12 weeks, the animals were evaluated for changes in the bodyweight and plasma glucose concentration. When hyperglycaemia reached high level in the dTg group (435 ± 108 mg/dL), the mice were anesthetized via an i.p. injection with a ketamine (100 mg/kg bodyweight)/xylazine (10 mg/kg bodyweight) cocktail for mice. After the blood was collected on 5 mmol/L EDTA through a ventricular puncture, the mice were perfused with phosphate buffered saline (PBS) and the kidneys were harvested and processed for further experimental assays. All animal experiments were conducted in accordance with ‘International Guiding Principles for Biomedical Research Involving Animals’ (Council for the International Organizations of Medical Sciences, December 2012), and regulations of the ethic Committee of ICBP ‘Nicolae Simionescu’ (approval number 373/27.06.2014).

2.2 Histological studies

Immediately after the standard cardiac perfusion with PBS, the left kidney of each animal was fixed by immersion in 10% formalin
for paraffin embedding. The 6-µm-thick sections, obtained with a Leica RM2245 microtome, were double stained, for cell nuclei with a modified haematoxylin solution and for cell structures with a modified 1% eosin solution (H&E Fast Staining Kit, Carl Roth GmbH + Co KG). For detection of collagen, Masson’s trichrome staining (Carl Roth GmbH + Co. KG) was used. The sections were mounted in 90% glycerol, examined on an AxioVert.A1 inverted microscope (Carl Zeiss GmbH) and analysed with Zen Pro 2012 Software (Carl Zeiss, GmbH).

2.3 | Protein extraction

From each animal, thirty milligrams of renal cortex tissue was mechanically homogenized (1 minutes) on ice in 0.3 mL buffer containing 8 M urea, 1% DOC and 100 mmol/L Tris-HCl (pH 7.5) and the samples were thereafter centrifuged (11 000 × g) at 4°C for 10 minutes. The supernatants were collected and stored at −30°C until use. All protein extracts were subsequently used for biochemical, mass spectrometry and Western blot (WB) quantification experiments.

2.4 | Preparation of kidney tissue samples for mass spectrometry analysis

After solubilization, 50 µg of proteins from each sample was further purified by acetone precipitation and incubated for 60 minutes at −20°C. The cysteine residues were processed in a reducing buffer (containing 8 M urea, 0.1 M Tris-HCl, 0.1 mol/L EDTA and 20 mmol/L DTT, pH 8.8) for 60 minutes, followed by alkylation using 80 mmol/L IAA in 0.1 M Tris-HCl and 0.1 mmol/L EDTA buffer, for 90 minutes, in the dark, with constant agitation (600rpm) at room temperature. Quenching was done using 80 mmol/L NAC in 0.1 M Tris-HCl and 0.1 mmol/L EDTA buffer, by shaking for 30 minues, at room temperature.

Proteolysis was performed overnight, at 37°C, using a 1:20 trypsin to substrate quantity ratio. Formic acid was added to the resulted peptide mixtures up to pH 2.5 for enzyme inhibition and DOC precipitation. The sedimented ionic detergent was discarded by centrifugation for 20 minutes, 20 000 × g at room temperature. The peptides were desalted using SPE and concentrated with the Concentrator plus system (Eppendorf).

2.5 | LC-MS/MS analysis

LC-MS/MS experiments were performed using an EASY-nLC II nano-liquid chromatography system coupled to an LTQVelos Pro Orbitrap mass spectrometer (Thermo Scientific). For chromatographic separation, a trap column (EASY column, 2 cm × 100 µm.d., C18, 5 µm, 120 Å, Thermo Scientific) was connected to the analytical column (EASY column, 10 cm × 75 µm.d., C18, 3 µm, 120 Å, Thermo Scientific) and a 90 minute, 3%-25% solvent B (acetonitrile with 0.1% [v/v] formic acid) over A (water with 0.1% [v/v] formic acid) separation gradient at a flow rate of 300 nL/min was applied. The MS was operated in a top 12 data-dependent configuration at 60k resolving power for a full scan across the 350-1700 m/z domain and collision-induced dissociation (CID) fragmentation mode for MS2. Each sample was injected in triplicate.

2.6 | Database protein identification, label-free quantification and data mining

Protein identification was performed using Proteome Discoverer 1.4 (Thermo Scientific) and Mascot 2.4.1 (Matrix Science), and the
taxonomy was set on Mus musculus organism in UniProtKB/SwissProt fasta database, build 11.2017. A maximum of 2 missed cleavage sites was allowed. Oxidation of methionine and deamidation of asparagine and glutamine were enabled as variable modifications while carbamidomethylation of cysteine was set as fixed modification. False discovery rate target was set below 0.05. SIEVE 2.1 software (Thermo Scientific) was used for label-free relative quantification of all identified proteins. A t test was employed to calculate p-value and to detect significant regulations (dTg/WT >1.5 or sTg/WT >1.5 or and dTg/WT <0.67 or sTg/WT <0.67 and P-value <.05) over ten biological replicates. Protein Center v 3.12 bioinformatics platform was utilized for projection of the quantitative data onto Kyoto Encyclopedia of Genes and Genomes (KEGG) signalling pathways and determine their over-representation (FDR P-value <.05). Proteins identified with a high Mascot score (>2) in the over-represented KEGG signalling pathways (FDR P-value <2.04E-02) in diabetic samples were further used for validation using as alternative methods, Western blot (WB) and gene expression assays.

### 2.7 Western blotting assay

Equal amounts of the renal tissue protein were loaded and separated by electrophoresis using 12.5% SDS polyacrylamide gels (SDS-PAGE). The proteins were subsequently transferred onto nitrocellulose membrane and analysed by Western blotting (WB) assay. The membranes were first exposed (2 hours) to the following primary antibodies: Cystathionine beta-synthase (Cbs mouse monoclonal, MA5-17273—Thermo Fisher Scientific, dilution 1:1000), sulphite oxidase, mitochondrial (Soxu rabbit polyclonal, PA5-21705—Thermo Fisher Scientific, dilution 1:1000), Thiosulphate sulphurtransferase (Tst rabbit monoclonal, ab166625—Abcam, dilution 1:1000) and β-actin (mouse monoclonal, ab6276—Abcam, dilution 1:1000) in TBS with 1% BSA. This was followed by the appropriate secondary antibodies (1 hour), IgG coupled with horseradish peroxidase (IgG–HRP). Beta-actin was used to normalize the semi-quantitative data. The reaction product was detected with the ECL Western blotting Substrate kit, and the protein bands were digitally detected (ImageQuant LAS4000) and quantified by densitometry with Scion Image software.

### 2.8 Gene expression analysis

Total RNA was extracted from kidney tissues using the RNaseq Mini Kit (Qiagen). Its quality was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies) and quantified by NanoDrop ND 1000 spectrophotometer (Thermo Scientific). The cDNA was generated from 1 μg total RNA using Transcriptor First Strand cDNA Synthesis Kit (Roche). Light Cycler 480 SYBR Green I Master mix was used to perform real-time PCR analysis in the Light Cycler System (Roche). All reactions were performed in triplicate, and the product specificity was validated by melting-curve analysis. Amplification of housekeeping gene b-actin was used for normalization. The primer sequences used were as follows: for Cbs 5′-GCTGGAACCTGCTCCTTTTC-3′ (forward) and 5′-GTCATGCGAATGGCTGAGAA-3′ (reverse); for Soxu 5′-GTGATGGGGACCCCTGAG-3′ (forward) and 5′-AATGCATGGAGACCCTGAG-3′ (reverse); for alpha-actin. 5′-AGTGTGACGTGACATCCGA-3′ (forward) and 5′-GCGAGACGAGTAATCTCCCT-3′ (reverse). The relative quantification of gene expression was done with LightCycler® 480 Software using the ΔΔCt (Efficiency)-Method.

### 2.9 Statistics

All the data were generated by running samples in triplicate and expressed as a mean ± SD. The results were analysed by Student’s unpaired t test using GraphPad Prism 5.0 statistical software (GraphPad Software). Significance was defined as a P-value <.05.

### 3 RESULTS

#### 3.1 Validation of the diabetic animal mode

At 13.5 weeks of age, the animals were euthanized and the relevant experimental parameters (bodyweight, glycemia, H₂S levels and others) were assessed comparatively in diabetic dTg mice and as controls, the non-diabetic sTg and wild-type mice (sTg and WT). The results showed that the average bodyweight of diabetic group decreased significantly by 1.3-fold (P ≤ .05). More so, the dTg demonstrated a ~3-fold increase over sTg group (P ≤ .001) and 5.6-fold vs WT (P ≤ .001) in plasma glucose concentration (Figure 1A). Moreover, the hyperglycaemic state of the diabetic animals was accompanied by a significant increase in plasma cholesterol compared to the values of the controls. The cholesterol values obtained for dTg were higher by ~1.2-fold vs WT (P ≤ .05) and by ~1.3 vs sTg (P ≤ .001) control groups (Figure 1B). Thus, these animals are hyperglycaemic and slightly hypercholesterolaemic, as it is often the case in diabetic patients.

The H₂S levels were measured in plasma and renal tissue homogenates using the methylene blue method according to the manufacturer’s instructions. Interestingly, the results showed that the H₂S levels in both the renal cortex and plasma increased significantly (by ~3.4-fold, P ≤ .05 and by ~1.9-fold, P ≤ .05, respectively) over the control samples (Figure 1C,D).

#### 3.2 Type-1 diabetes induces subtle structural changes of kidney tissue

Staining of renal tissue sections with haematoxylin-eosin showed no histological abnormalities in the kidney isolated from the control
groups (WT and sTg). Diabetic kidney tissue from the dTg group exhibited an apparently normal structure of the glomeruli and the Bowman's capsules, as well. However, the Masson's trichrome staining (Figure 2A-C) evidenced minor variations in the tubulointerstitial structure of the diabetic kidney. Thus, in the dTg kidney sections we detected the presence of interstitial fibrosis surrounding the uriniferous tubules (Figure 2C, blue staining) and a ~10% (P ≤ .001) increase of the mean area of glomeruli compared to control samples (Figure 2D).

### 3.3 Modifications of kidney proteome in T1D revealed by global shotgun proteomic analysis

Nano-liquid chromatography coupled with tandem mass spectrometry (nLC-MS/MS) experiments were applied on samples of homogenates of renal cortex isolated from dTg, sTg and WT mice. The data led to the identification of 351 proteins that were uniquely identified in dTg, 467 were found only in sTg, while 549 were uniquely attributed to the WT group (Figure 3A). Among all the identified proteins (4261), we also found (average Mascot Score >100) nine of the most frequently studied urinary biomarkers for diabetic nephropathy, supporting the reliability of our method (listed in Table S1 as supplementary data).

The dTg and sTg proteomes were normalized over the WT mice and the resulting differentially abundant proteins were retained for further comparative analysis (Figure 3B). Thus, 106 proteins (7 up-regulated and 99 down-regulated) were found to be uniquely and differentially expressed in sTg/WT, while 144 (120 up-regulated and 24 down-regulated) exhibited a significantly altered abundance only in diabetic kidney group, dTg/WT. Finally, 313 proteins (210 up-regulated and 103 down-regulated) were common to both groups (Figure 3B). Worth mentioning is that, compared to controls, the majority of proteins (120 out of 144) were up-regulated in the diabetic group.

Gene ontology analysis of the entire set of 144 differentially abundant proteins induced by diabetic condition revealed that mitochondrion (89 proteins), small molecule metabolic process (70 proteins) and oxidoreductase activity categories (111 proteins) were statistically over-represented. The relevant gene ontology classification data (by Cellular Components, Biological Processes, and Molecular Functions) for the differentially expressed proteins in diabetic dTg/WT mice are included as supporting information in Table S2 as supplementary data.

The quantitative analysis comparing dTg and sTg with WT sets indicated 56 statistically significant differentially abundant proteins (Table S3 as supplementary data) involved in nine statistically over-represented KEGG pathways (FDR P-value <2.04E-02) just in the diabetic samples (Table 1). This analysis evidenced ten enzymes related to the sulphur metabolism. Six of them were found to be involved in the first KEGG pathway (mmu00920- highest FDR corrected p-value) and are implicated in sulphate activation and degradation and in H2S clearance and four of them were responsible for the H2S production. Figure 4A shows the abundance of the enzymes up-regulated in the diabetic kidney as compared to control: bifunctional 3'-phosphoadenosine 5'-phosphosulphate synthase 2 (Papps2), sulphidequinone oxidoreductase (Sqr2ld), thiosulphate sulphur transferase (Tst), sulphite oxidase (Suox), protein Ethel1 mitochondrial (Ethel1) and cystathionine γ-lyase (Cth).

In contrast, 3(2)5 bisphosphate nucleotidase 1 (Bpnt1), cystathionine β-synthase (Cbs), 3- mercaptoproprionate sulphur transferase

**FIGURE 2** Representative images of Masson’s trichrome staining of kidney tissue sections (A-C). Note that the diabetic kidney tissue exhibits marked interstitial fibrosis (blue stained) surrounding the uriniferous tubules (C, arrows). Morphometric analysis (D) shows that the mean area of glomeruli was significantly increased in diabetic kidney tissue compared to non-diabetic controls. Data are expressed as mean ± SD; ***P < .001
UYY et al. found that D-amino acid oxidase (Dao) was significantly down-regulated in diabetic kidney (Figure 4A). These enzymes were previously shown to have specific metabolic functions and to be responsible for the bioavailability of sulphate and the H₂S homeostasis in different experimental models and biological mechanisms (see Figure 4C).

The results reported above for Cbs, Suox and Tst were validated by Western blot and real-time PCR assays. Thus, the immunoassays revealed the down-regulation of Cbs (∼2.5-fold, \( P \leq .01 \)) and the up-regulation of Suox (∼1.6-fold, \( P \leq .01 \)) and Tst (∼1.5-fold, \( P \leq .01 \)) macromolecules in the diabetic kidney (Figure 4B). These results confirmed and were in good agreement with the mass spectrometry data.

In addition, the Cbs and Suox gene expression was verified in the kidney homogenates by real-time PCR. The results back up and support the data obtained by MS and immunoassay, confirming the down-regulation of Cbs gene expression (by ∼1.8-fold, \( P \leq .05 \)) and the up-regulation of Suox molecule (∼2.3-fold, \( P \leq .01 \)) in diabetic renal tissue (Figure 5A,B).

**DISCUSSION**

This study was designed to uncover the debated role of H₂S in kidney dysfunction that is characteristic for T1D. To this purpose, we took advantage of the availability of the global comparative shotgun proteomic analysis and of the accessibility to a double transgenic mouse model (dTg) which develops T1D. These mice exhibit hyperglycaemia, mild hypercholesterolaemia, weight loss and early kidney dysfunction, the latter revealed by the subtle histological alterations of the kidney tissue. These results corroborate well with previously published data on dTg mice, which develop autoimmune T1D via a gradual process associated with low level of plasma insulin and glycosuria. Importantly, this mouse model exhibits characteristics similar to those described in human patients, as ‘near normal diabetic nephropathy’ or Class I diabetic nephropathy. This is supported by our histological results (Figure 2) demonstrating an early activation of the fibrotic pathways at the kidney level, together with the lower spectral abundance of heparan sulphate proteoglycan 2 and uromodulin.
The latter are two important protein markers of early kidney injury, indicating an uncomplicated diabetes without major damage of renal tissue.

The global gene ontology characterization of differentially abundant proteins revealed their association with mitochondrion and oxidoreductase activity (see Table S2 as supplementary data). These data extend the observations made in diabetic animal models and humans, which state that mitochondrial dysfunction is at the centre of renal disease development and progression.

Using a TID mouse model and relative quantitative proteomic analysis, we unambiguously revealed the deregulated tissue protein levels of Papp2, Bpnt1, Sqrdl, Tst, Suox and Ethel enzymes. These were associated with minor structural changes in the kidney tissue suggesting novel and alternative mechanisms for the generation of early nephropathy in TID.

LC-MS/MS results revealed that enzymatic sulphate activation is affected by up-regulation of Papp2 and the down-regulation of Bpnt1. The latter removes cytoplasmic Pap, the otherwise toxic by-product of sulfation. Our data also showed that hyperglycaemia induces a decrease of Bpnt1 protein expression correlated with renal tissue damage, data that concur with studies disclosing that the kidney proximal tubule epithelial cells are affected in the Bpnt1 knockout mouse.

Although often overlooked, a low concentration of hydrogen sulphide has a role in the regulation of physiological homeostasis. Clearance of accumulated toxic levels of hydrogen sulphide in the
tissues occurs mainly by mitochondrial oxidation pathways through a respiratory route. This pathway has established hydrogen sulfide as the first non-carbon-based respiratory fuel in mammalian systems.\(^{23,24}\) In this study, we detected the up-regulation of mitochondrial Sqrdl, Tst and Suox, Ethe1 enzymes, which are implicated in H\(_2\)S oxidation pathway, one of the hydrogen sulphide clearance mechanisms mentioned above. It is safe to assume that in early diabetic nephropathy, impaired sulphide oxidation, plays an important part in the oxidative stress-mediated kidney damage.

There are reports indicating a tight correlation between the protein expression of Cth and Cbs with renal tissue H\(_2\)S production induced by diabetes.\(^{3}\) Indeed, in our experiments the two enzymes, as well as Mpst and Dao, were found to be significantly down-regulated in diabetic condition (Figure 4A). Under physiological conditions, the level of renal Cth protein was reported to be ~20-fold higher than Cbs, suggesting that the former may be the main H\(_2\)S-forming enzyme in the kidney.\(^{25}\) From our data, the differential abundance of selected enzymes (Cth, Cbs, Mpst and Dao), associated with kidney H\(_2\)S production, correlates well with the increased H\(_2\)S level detected in plasma and kidney homogenate (Figures 4 and 1C,D). These data are in good agreement with previous findings stating that H\(_2\)S production is sustained with the increased H\(_2\)S level detected in plasma and kidney homogenate (Figures 4 and 1C,D). These data are in good agreement with previous findings stating that H\(_2\)S production is sustained by overexpression of tissue Cth in response to diabetes.\(^{26}\) There are reports recognizing that in streptozotocin-induced diabetic rats, renal H\(_2\)S-producing enzymes Cbs and Cth are down-regulated.\(^{10}\) Our results confirmed the down-regulation of Cbs, but not Cth protein. This discrepancy could relate to our model, which exhibits early-stage diabetic kidney disease that differs from advanced chronic nephropathy occurring in streptozotocin-induced diabetes.

The effect of a high concentration of H\(_2\)S in the plasma and kidney tissue of diabetic patients is controversial. Some reports claim that H\(_2\)S exhibits vascular-protective effects, causing vasodilation in diabetes\(^{27,28}\) and reducing vascular smooth muscle proliferation.\(^{29,30}\) Others describe that H\(_2\)S may promote apoptosis of aortic smooth muscle cells,\(^{31}\) and scavenges peroxynitrite\(^{32}\) which contributes to the nitrosative stress,\(^{33}\) and consequently to endothelial damage associated with this condition.\(^{34}\)

In our experiments, the T1D mice, non-obese, non-overweight and exhibiting an early Class I (like) diabetic nephropathy, exhibited elevated levels of plasma H\(_2\)S (Figure 1C,D), as reported for patients with proliferative diabetic retinopathy\(^{34,35}\) and cardiovascular disease.\(^{36}\)

It is important to emphasize that the amplified level of H\(_2\)S was present in the renal cortex of T1D animals. This is in contrast to previous data reporting reduced H\(_2\)S content in diabetic acute (formerly known as acute renal failure) or chronic nephropathy.\(^{5,37-39}\) This discrepancy could be due to the difference between the early stage of diabetic kidney disease without advanced pathological alterations, and the chronic nephropathy characterized by glomerular basement membrane thickening, mesangial matrix deposition and renal interstitial fibrosis.

Several therapies are currently indicated to regulate the abnormal H\(_2\)S content in order to ameliorate advanced renal injury in diabetes.\(^{17,40}\) One can envisage the need for therapeutic interventions for the early stages of diabetic nephropathy to delay or halt its progression.

In summary, these experiments showed that the mechanism underlying the elevated renal and plasma H\(_2\)S content in early T1D nephropathy relates to the deregulated—differential expression of specific renal enzymes involved in sulphate activation and degradation, H\(_2\)S production and clearance mechanisms.\(^{5}\)

Based on these novel findings, we can safely assume that the dysregulation of the enzymes involved in H\(_2\)S metabolism plays a significant part in the aetiology of nephropathy in diabetes and may recommend them as new targets for the therapy of T1D.

### 5 | FAIR DATA SHARING

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE\(^{41-43}\) partner repository with the data set identifier PXD018053.
ACKNOWLEDGEMENTS
The present work was supported by the Romanian Academy and partially for technological support by the Romanian National Authority for Scientific Research and Innovation, CCCDI-UEFISCDI [project number 41/2018 COFUND-ERA-CVD-XploreCAD, within PNCDI III]. The authors are grateful for the constructive discussion regarding the pathology of diabetes with Professor Constantin Ionescu-Târgoviște, University of Medicine and Pharmacy ‘Carol Davila’, Bucharest, Romania.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTION
Elena Uyy: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Validation (equal); Writing-original draft (equal). Viorel Iulian Suica: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Writing-original draft (equal). Raluca Maria Boteanu: Data curation (equal); Formal analysis (equal); Methodology (equal). Florentina Safciuc: Methodology (equal); Visualization (equal). Elena Uyy: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Validation (equal); Writing-original draft (equal). Maya Simionescu: Resources (equal); Writing-review & editing (equal). Felicia Antohe: Conceptualization (equal); Formal analysis (equal); Funding acquisition (equal); Project administration (equal); Resources (equal); Supervision (equal); Writing-original draft (equal); Writing-review & editing (equal). Raluca Maria Boteanu: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal). Maya Simionescu: Resources (equal); Writing-review & editing (equal). Raluca Maria Boteanu: Data curation (equal); Formal analysis (equal); Methodology (equal). Florentina Safciuc: Methodology (equal); Visualization (equal). Elena Uyy: Data curation (equal); Formal analysis (equal); Investigation (equal); Methodology (equal); Software (equal); Validation (equal); Writing-original draft (equal).

DATA AVAILABILITY STATEMENT
Data openly available in a public repository that issues datasets with DOIs.

ORCID
Felicia Antohe https://orcid.org/0000-0002-3325-2867

REFERENCES
1. Habib SL. Diabetes and renal tubular cell apoptosis. World J Diabetes. 2013;4(2):27-30.
2. Popov D, Simionescu M. Structural and transport property alterations of the lung capillary endothelium in diabetes. Ital J Anat Embryol. 2001;106:405-412.
3. Deggermann S, Reilly C, Scott B, Ogata L, von Boehmer H, Lo D. On the various manifestations of spontaneous autoimmune diabetes in rodent models. Eur J Immunol. 1994;24(12):3155-3160.
4. Radu DL, Georgescu A, Stavaru C, Barale A, Popov D. Double transgenic mice with Type 1 diabetes mellitus develop somatic, metabolic and vascular disorders. J Cell Mol Med. 2004;8:349-358.
5. van den Born JC, Hammes HP, Greffrath W, et al. Gastrotransmitters in vascular complications of diabetes. Diabetes. 2016;65:331-345.
6. Cao X, Bian JS. The role of hydrogen sulfide in renal system. Front Pharmacol. 2016;7:385.
7. Xie L, Gu Y, Wen M, et al. Hydrogen sulfide induces Keap1 S-sulfhydration and suppresses diabetes-activated atherosclerosis via Nrf2 activation. Diabetes. 2016;65:3171-3184.
8. Yang G, Tang G, Zhang L, Wu L, Wang R. The pathogenic role of cystathionine -lyase/hydrogen sulfide in streptozotocin-induced diabetes in mice. Am J Pathol. 2011;179(2):869-879.
9. Suzuki K, Olah G, Modis K, et al. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA. 2011;108:13829-13834.
10. Zhou X, An G, Lu X. Hydrogen sulfide attenuates the development of diabetic cardiomyopathy. Clin Sci (Lond). 2015;128:325-335.
11. Zhou X, Feng Y, Zhan Z, Chen J. Hydrogen sulfide alleviates diabetic nephropathy in a streptozotocin-induced diabetic rat model. J Biol Chem. 2014;289:28827-28834.
12. Durante W. Hydrogen sulfide therapy in diabetes accelerated atherosclerosis: a whiff of success. Diabetes. 2016;65:2832-2834.
13. Sun HJ, Wu ZY, Cao L, et al. Hydrogen sulfide: recent progress and perspectives for the treatment of diabetic nephropathy. Molecules. 2019;24(15):2857.
14. Jain SK, Bull R, Rails J, et al. Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? Antioxid Redox Signal. 2010;12(11):1333-1337.
15. Yousuf M, Kwong HBT, Hsu A, Whiteman M, Bhatia M, Moore PK. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochim Biophys Res Commun. 2005;333:1146-1152.
16. Dutta M, Biswas UK, Chakraborty R, Banerjee P, Roychadhuri U, Kumar A. Evaluation of plasma H2S levels and H2S synthesis in streptozotocin induced Type 2 diabetes-an experimental study based on Swietianiamacrophylla seeds. Asian Pac J Trop Biomed. 2014;4(4):S483-S487.
17. Van JA, Scholey JW, Konvalinka A. Insights into diabetic kidney disease using urinary proteomics and bioinformatics. J Am Soc Nephrol. 2017;28:1050-1061.
18. Boteanu RM, Suica VI, Uyy E, et al. Alarmins in chronic noncommunicable diseases: atherosclerosis, Diabetes and Cancer. J Proteomics. 2017;153:21-29.
19. Uyy E, Antohe F, Ivan L, Haraba R, Radu DL, Simionescu M. Upregulation of caveolin-1 expression is associated with structural modifications of endothelial cells in diabetic lung. Microvasc Res. 2010;79(2):154-159.
20. Boteanu RM, Uyy E, Suica VI, Antohe F. High-mobility group box 1 enhances the inflammatory process in diabetic lung. Arch Biochem Biophys. 2015;583:55-64.
21. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556-563.
22. Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14:291-312.
23. Hudson BH, York JD. Tissue-specific regulation of 3-nucleotide hydroylsis and nucleolar architecture. Adv Biol Regul. 2014;54:208-213.
24. Carter RN, Morton NM. Cysteine and hydrogen sulphide in the regulation of metabolism: insights from genetics and pharmacology. J Pathol. 2016;238:321-332.
25. Dugbartey GJ. Diabetic nephropathy: a potential savior with ‘rotten-egg’ smell. Pharmacol Rep. 2017;69:331-339.
26. Goubert M, Andriamihaja M, Nubel T, Blachier F, Boullaud F. Sulfide, the first inorganic substrate for human cells. FASEB J. 2007;21:1699-1709.
27. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791-896.
28. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17:165-205.
29. Zhao W, Wang R. H2S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol. 2002;283:H474-H480.
30. Du J, Hui Y, Cheung Y, et al. The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels. 2004;19:75-80.
31. Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen activated protein kinases and caspase-3. FASEB J. 2004;18:1782-1784.
32. Whiteman M, Armstrong JS, Chu SH, et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite scavenger? J Neurochem. 2004;90:765-768.
33. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Baylis C. Peroxynitrite versus nitric oxide in early diabetes. Am J Hypertens. 2003;16:761-766.
34. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004;11:89-97.
35. Ran R, Du L, Zhang X, et al. Elevated hydrogen sulfide levels in vitreous body and plasma in patients with proliferative diabetic retinopathy. Retina. 2014;34(10):2003-2009.
36. Saha P, Banerjee P, Pal P, et al. Enhanced plasma H2S levels associated with fasting blood glucose in Type-2 diabetes mellitus. Asian J Med Sci. 2015;6(6):11-15.
37. Peter EA, Shen X, Shah SH, et al. Plasma free H2S levels are elevated in patients with cardiovascular disease. J Am Heart Assoc. 2013;2:e000387.
38. Cao X, Zhang W, Moore PK, Bian J. Protective smell of hydrogen sulfide and polysulfide in cisplatin-induced nephrotoxicity. Int J Mol Sci. 2019;20:313.
39. Koning AM, Frenay AR, Leuvenink HG, van Goor H. Hydrogen sulfide in renal physiology, disease and transplantation - The smell of renal protection. Nitric Oxide Biol Chem. 2015;46:37-49.
40. Lobb I, Sonke E, Aboalsamh G, Sener A. Hydrogen sulphide and the kidney: Important roles in renal physiology and pathogenesis and treatment of kidney injury and disease. Nitric Oxide Biol Chem. 2015;46:55-65.
41. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47(D1):D442-D450.
42. Deutsch EW, Csordas A, Sun Z, et al. The ProteomeXchange Consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017;54(D1):D1100-D1106.
43. Perez-Riverol Y, Xu QW, Wang R, et al. PRIDE inspector tool suite: moving towards a universal visualization tool for proteomics data standard formats and quality assessment of ProteomeXchange datasets. Mol Cell Proteomics. 2016;15(1):305-317.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Uyy E, Suica VI, Boteanu RM, et al. Diabetic nephropathy associates with deregulation of enzymes involved in kidney sulphur metabolism. J Cell Mol Med. 2020;24:12131-12140. https://doi.org/10.1111/jcmm.15855